期刊文献+

国内7个厂家静注人免疫球蛋白产品成分分析 被引量:13

Composition analysis of intravenous immunoglobulin from seven Chinese blood fractionation industries
原文传递
导出
摘要 目的调查国内7个厂家静注人免疫球蛋白(IVIG)制品中各种免疫球蛋白成分含量,为改进国产IVIG质量提供参考依据。方法采用ELISA法测定市售的国内7家血液制品厂生产的26批次IVIG制品中IgG、IgA、IgD、IgE、IgM等免疫球蛋白的含量以及IgG亚型含量;同时测定进口某品牌6批次IVIG制品做对照。结果免疫球蛋白含量国内与进口制品比较,IgG(g/mL):0.052±0.003 vs 0.048±0.003;IgA(μg/mL):154.1±30.8 vs 120.3±52.5;IgM(μg/mL):7.6±1.5 vs 4.7±5.0;IgD(ng/mL):145.5±29.1 vs 207.8±23.9;IgE(ng/mL):13.9±2.7vs 93.7±17.8;IgG亚型含量IgG1(%):58.4±3.3 vs 60.4±2.1;IgG2(%):32.0±2.9 vs 31.5±1.8;IgG3(%):7.0±1.1 vs 6.4±0.5;IgG4(%):2.6±1.1 vs 1.7±0.9。结论国内外不同厂家的IVIG制品中IgG含量、IgG亚型差异不明显,均接近正常血浆比例,达到药典相关规定。除IgM含量外IgA、IgD、IgE等含量差异较明显(P<0.05)。 Objective To investigate the composition of intravenous immunoglobulin from seven domestic blood fraction- ation industries,and try to provide references for improving domestic WIG product quality. Methods The contents of IgG, IgA,IgD,IgE,IgM and IgG subclasses of all 1VIG samples were determined by ELISA. Results We investigate 26 batches of IVIG from seven domestic industries and 6 batches from a foreign manufacturer for comparison. Average results are described bellow ( domestic vs foreign ) : IsG(g/mL):0.052±0.003 vs 0.048±0.003;IgA(pg/mL):154.1±30.8 vs 120.3±52.5;IsM(μg/mL):7.6±1.5 vs 4.7±5.0;IgD(ng/mL):145.5±29.1 vs 207.8±23.9;IgE(ng/mE):13.9±2.7 vs 93.7±17.8;IgG subclass IgG1(%):58.4±3.3 vs 60.4±2.1;IgG2(%):32.0±2.9 vs 31.5±1.8;IgG3(%):7.0±1.1vs6.4±0.5;IgG4(%):2.6±1.1 vs 1.7±0.9. Conclusion All I~]G in our investigation have no significant differences in IgG levels and IgG subclasses contents, and all meet the quality requirements of the Chinese Pharmacopoeia. However,other immtmoglobulin except IgM were significantly different between domestic products and foreign ones.
出处 《中国输血杂志》 CAS CSCD 北大核心 2014年第1期40-42,共3页 Chinese Journal of Blood Transfusion
基金 协和青年科研基金项目(3332013110)
关键词 静注入免疫球蛋白 免疫球蛋白组分 IgG含量 IGG亚型 其他免疫球蛋白 intravenous immunoglobulin immunoglobulin component IgG IgG subclass other immunoglobulin
  • 相关文献

参考文献10

  • 1Lemieux R, Razin R, Neron S: Therapeutic intravenous immuno- globulins. Mol Immunol. 2005,42:839-848.
  • 2Burnouf T: Modern plasma fractionation. Transfus Med Rev. 2007, 21:101-117.
  • 3Radosevich. M. Burnouf T: Intravenous immunoglobulin G : trends in production methods, quality control and quality assurance. Vox Sari- guinis. 2010,98 : 12-28.
  • 4刘鹏翰.静脉注射免疫球蛋白概况[J].中国输血杂志,1994,7(3):155-158. 被引量:3
  • 5Jordan S, Elham M, Catherine tl.,et al: Use of intravenous immuno- globulin in human disease: A review of evidence by membersof the Primary Immunode? ciency Committee of the American Academy of Allergy,Asthma and Immunology. J Allergy Clin Immunol. 2006, 117:525-553.
  • 6Council of European : Eupepean Pharmacopeia 7.0 : Human normal immunoglobulin for intravenous administration. 2008.
  • 7Etscheid M, Breitner S, Gross S, et al : ldenti? cation of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implica- tions for the safety and control of intravenous bloom products. Vox Sanguinis. 2012,102( 1 ) :40-46.
  • 8Octaphama: Summary of product characten'stics, Human nomlal im- munoglobulin for intravenous administration, OCTAGAM 5%.
  • 9Norrby TA, Haque KN, Hammarstr? m L: Intravenous polyclonal lgM-enfiched immunoglobulin therapy in sepsis: a review of clini- cal efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med. 2006,260(6) :509-516.
  • 10任跃明,程雅琴,倪道明.静脉注射人免疫球蛋白的质量控制[J].中国生物制品学杂志,2005,18(1):73-75. 被引量:12

二级参考文献1

共引文献13

同被引文献85

  • 1何江玲.应用人免疫球蛋白联合氨溴索治疗新生儿医院感染性肺炎的疗效观察[J].当代医药论丛,2014,12(7):159-160. 被引量:7
  • 2Alzheimer's A. 2014 Alzheimer's disease facts and figares. Alzhe- imers Dement, 2014, 10 (2) : e47-92.
  • 3Wilhelmus MM, De Wa',d RM,Verbeek MM. Heat shck protcins and amateur chaperones in amyloid-Beta accumulation mid clearance in Alzheimer's disease. Mol Neurobiol, 2007, 35 (3) : 203-216.
  • 4Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer' s dis- ease: progress and problems on the road to therapeutics. Science, 2002, 297 (5580) : 353-356.
  • 5Martin P MP, Malenn G. The World Alzheimer Report 2013 ' Journey of Caring: An analysis of long-term care for dementia' Alzheimer' s Disease International, 2013,18-19.
  • 6Gandy S, Dekosky ST. Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress. Annu Rev Meal, 2013:64 367-383.
  • 7Martin P, Matthew P,Malerm G. The World Alzhelrner Report 2013 'Journey ff Caring: An analysis of long-term care for dementia' . Alzheimer' s Disease International (ADI), London, 2013:165-177.
  • 8Teich AF,Arancio O. Is the amyloid hypothesis of Alzheimer's disease thempoutieally relevant? Bioehem o, 2012,446(2) : 165-177.
  • 9.ennow K, Hampel H, Zetterberg H. Biomarkers in arayloid-beta immunotherapy trials in Alzheimer's disease. Neuropsychopharma- cology, 2014, 39 (1): 189-201.
  • 10Yipoulou KG,Papogeorgiou SG. Cunnt and future treatments for Alzheimer's disease. Ther Adv Neurol Disord, 2013, 6 (1) : 19-33.

引证文献13

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部